SG10201900564WA - Methods for treating cancer - Google Patents

Methods for treating cancer

Info

Publication number
SG10201900564WA
SG10201900564WA SG10201900564WA SG10201900564WA SG10201900564WA SG 10201900564W A SG10201900564W A SG 10201900564WA SG 10201900564W A SG10201900564W A SG 10201900564WA SG 10201900564W A SG10201900564W A SG 10201900564WA SG 10201900564W A SG10201900564W A SG 10201900564WA
Authority
SG
Singapore
Prior art keywords
methods
treating cancer
compound
kits
administering
Prior art date
Application number
SG10201900564WA
Other languages
English (en)
Inventor
Chiang Li
Wei Li
Youzhi Li
Matthew Hitron
Yuan Gao
Original Assignee
Boston Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical Inc filed Critical Boston Biomedical Inc
Publication of SG10201900564WA publication Critical patent/SG10201900564WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG10201900564WA 2015-04-17 2016-04-18 Methods for treating cancer SG10201900564WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562149349P 2015-04-17 2015-04-17
US201662280947P 2016-01-20 2016-01-20

Publications (1)

Publication Number Publication Date
SG10201900564WA true SG10201900564WA (en) 2019-02-27

Family

ID=55854799

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201708504XA SG11201708504XA (en) 2015-04-17 2016-04-18 Methods for treating cancer
SG10201900564WA SG10201900564WA (en) 2015-04-17 2016-04-18 Methods for treating cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201708504XA SG11201708504XA (en) 2015-04-17 2016-04-18 Methods for treating cancer

Country Status (16)

Country Link
US (1) US20180085341A1 (enExample)
EP (1) EP3283069A1 (enExample)
JP (1) JP2018511643A (enExample)
KR (1) KR20180006918A (enExample)
CN (1) CN107666906A (enExample)
AU (1) AU2016247319A1 (enExample)
BR (1) BR112017022281A2 (enExample)
CA (1) CA2983010A1 (enExample)
EA (1) EA201792287A1 (enExample)
HK (1) HK1250944A1 (enExample)
IL (1) IL255022A0 (enExample)
MX (1) MX2017013360A (enExample)
PH (1) PH12017501879A1 (enExample)
SG (2) SG11201708504XA (enExample)
TW (1) TW201713327A (enExample)
WO (1) WO2016168856A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105963289B (zh) 2007-09-10 2021-02-26 北京强新生物科技有限公司 一类stat3通路抑制剂和癌干细胞通路抑制剂
SG11201508358RA (en) 2013-04-09 2015-11-27 Boston Biomedical Inc 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
WO2017132049A1 (en) * 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
EP3678663A4 (en) * 2017-09-05 2021-06-02 Epizyme, Inc. POLYTHERAPY FOR CANCER TREATMENT
EP3865130A4 (en) 2018-10-12 2022-07-20 1Globe Biomedical Co., Ltd. NEW COMBINATION SOLUTION FOR THE TREATMENT OF CHEMOTHERAPY-REFRACTORY CANCER
EP3705893A1 (en) * 2019-03-05 2020-09-09 Humanitas Mirasole S.p.A. Methods to assess the risk of being affected by prostate cancer
SG11202110338XA (en) * 2019-03-27 2021-10-28 Singapore Health Serv Pte Ltd Biomarker with therapeutic implications for peritoneal carcinomatosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105963289B (zh) * 2007-09-10 2021-02-26 北京强新生物科技有限公司 一类stat3通路抑制剂和癌干细胞通路抑制剂
RU2591823C2 (ru) 2010-03-19 2016-07-20 Бостон Байомедикал, Инк. Новые способы направленного воздействия на раковые стволовые клетки
ES2659541T3 (es) 2010-03-19 2018-03-16 1Globe Biomedical Co., Ltd. Compuestos y composiciones novedosas para direccionar hacia células madre del cáncer
WO2012119265A1 (en) 2011-03-04 2012-09-13 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. NOVEL ESTERS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR DISEASE THERAPIES
US8977803B2 (en) 2011-11-21 2015-03-10 Western Digital Technologies, Inc. Disk drive data caching using a multi-tiered memory
WO2013166618A1 (en) * 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
SG11201508358RA (en) * 2013-04-09 2015-11-27 Boston Biomedical Inc 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
WO2017132049A1 (en) * 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer

Also Published As

Publication number Publication date
CN107666906A (zh) 2018-02-06
SG11201708504XA (en) 2017-11-29
TW201713327A (zh) 2017-04-16
US20180085341A1 (en) 2018-03-29
MX2017013360A (es) 2018-08-01
EP3283069A1 (en) 2018-02-21
IL255022A0 (en) 2017-12-31
HK1250944A1 (zh) 2019-01-18
EA201792287A1 (ru) 2018-03-30
BR112017022281A2 (pt) 2018-07-10
PH12017501879A1 (en) 2018-03-05
AU2016247319A1 (en) 2017-11-02
WO2016168856A1 (en) 2016-10-20
JP2018511643A (ja) 2018-04-26
KR20180006918A (ko) 2018-01-19
CA2983010A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
SG10201900564WA (en) Methods for treating cancer
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
ZA201605715B (en) Cyclopropylamines as lsd1 inhibitors
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
IL253979A0 (en) Methods, preparations and kits for cancer treatment
NZ724691A (en) Quinoline derivatives as smo inhibitors
PL3377516T3 (pl) Kompozycja do leczenia nowotworu
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
PH12015501997A1 (en) Compositions and methods for diagnosis and treatment of hepatic cancers
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2016009663A (es) Derivados de icariina.
MX2017000312A (es) Derivados de isoindolina para usarse en el tratamiento de una infeccion viral.
MX2016014559A (es) Compuestos para el tratamiento de cancer.
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
MX375438B (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
MX380689B (es) Tratamiento de cancer con dihidropirazino-pirazinas.
MX2016005393A (es) Metodos para tratar vhc.
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
PH12017501880A1 (en) Methods for treating cancer
MX2015013021A (es) 5-bromo-indirrubinas.
MX2015012523A (es) Metodos para elaborar composiciones antineoplasicas.
CY1125266T1 (el) To rad1901 για χρηση στη θεραπεια του καρκινου των ωοθηκων